Skip to main content

Table 4 Perceptions of community pharmacists towards pharmacogenomics services

From: Knowledge, attitude and perception of community pharmacists towards pharmacogenomics services in northern Nigeria: a cross-sectional study

Variables Frequency (%)
Strongly agree Agree Neutral Disagree Strongly disagree
Community pharmacists are well-placed within the healthcare system to provide pharmacogenomics services 29 (18.0) 31 (19.3) 29 (18.0) 31 (19.3) 40 (24.8)
Pharmacogenomics testing services is feasible in community pharmacy setting 34 (21.1) 36 (22.4) 38 (23.6) 40 (24.8) 12 (7.5)
Community pharmacists have the expertise to interpret and adjust medication doses based on patient’s pharmacogenomics results 36 (22.4) 50 (31.1) 42 (26.1) 12 (7.5) 20 (12.4)
Community pharmacists need training in pharmacogenomics 91 (56.5) 50 (31.1) 14 (8.7) 2 (1.2) 1 (0.6)
Physicians and community pharmacists should collaborate to offer pharmacogenomics testing 103 (64.0) 49 (30.4) 6 (3.7) 2 (1.2)  
Pharmacogenomics testing will prevent your patient from taking the inappropriate medicine or the wrong dose 97 (60.2) 49 (30.4) 11 (6.8) 2 (1.2) 1 (0.6)
Incorporation of pharmacogenetic screening into medication therapy management will optimize pharmacotherapy 65 (40.4) 75 (46.6) 15 (9.3) 3 (1.9)  
Pharmacogenomics testing will become a routine in clinical practice in the future 54 (33.5) 43 (26.7) 31 (19.3) 26 (16.1) 5 (3.1)
Pharmacogenomics-guided treatment is cost-effective 40 (24.8) 68 (42.2) 29 (18.0) 7 (4.3) 11 (6.8)
Barriers to implementation of pharmacogenomics services
 Lack of knowledge 86 (53.4) 58 (36.0) 8 (5.0) 2 (1.2) 2 (1.2)
 Lack of reimbursement 71 (44.1) 60 (37.3) 16 (9.9) 5 (3.1) 2 (1.2)
 Lack of time 63 (39.1) 53 (32.9) 25 (15.5) 10 (6.2) 3 (1.9)
 Lack of guidelines 82 (50.9) 59 (36.6) 8 (5.0) 5 (3.1) 1 (0.6)
 Ethical considerations regarding ownership of genetic data 77 (47.8) 44 (27.3) 28 (17.4) 2 (1.2) 3 (1.9)
 Resistance from other healthcare professionals 74 (46.0) 52 (32.3) 24 (14.9) 4 (2.5) 1 (0.6)
 Lack of acceptance by patients 78 (48.4) 40 (24.8) 22 (13.7) 8 (5.0) 7 (4.3)